Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
958.64
+1.64 (+0.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regeneron Pharmaceuticals
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
31
32
Next >
Why Shares of Regeneron Are Rising Thursday
March 23, 2023
Regeneron released positive phase 3 trial results for its therapy Dupixent.
Via
The Motley Fool
Why Are Stocks Up Today?
March 23, 2023
Stocks are up today as investors react to the latest news from the Federal Reverse concerning a new interest rate increase.
Via
InvestorPlace
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
March 23, 2023
Via
Benzinga
REGN Stock Alert: Regeneron Pharmaceuticals Gains on Dupixent Drug Data
March 23, 2023
Regeneron Pharmaceuticals (REGN) stock is on the rise Thursday after the company released its latest clinical trial data on Dupixent.
Via
InvestorPlace
This Is What Whales Are Betting On Regeneron Pharmaceuticals
March 23, 2023
Via
Benzinga
Apple Jumps Movie Production Bandwagon, Billionaire Jim Ratcliffe Bids For Manchester United, Elon Musk Seeks Funding For SpaceX From Middle-Eastern Fund: Today's Top Stories
March 23, 2023
Bloomberg
Via
Benzinga
Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung'
March 23, 2023
The companies' Dupixent reduced exacerbations by 30%.
Via
Investor's Business Daily
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,200 Today
March 16, 2023
Via
Benzinga
Why Regeneron Pharmaceuticals And Sanofi Shares Are Trading Higher Today
March 23, 2023
Sanofi-Regeneron stocks are trading higher today after their blockbuster drug aced the pivotal COPD trial.
Via
Benzinga
7 Value Stocks Worth Buying at These 52-Week Highs
March 22, 2023
While these value stocks to buy are trading near their 52-week highs, they still have plenty of gas left in the tank for investors.
Via
InvestorPlace
Week In Review: Livzon In-Licenses GERD Therapy In $127 Million Agreement
March 18, 2023
Livzon Pharmaceutical Group entered a $127.5 million agreement for China rights to a gastroesophageal reflux disease therapy from Onconic Therapeutics. Meanwhile, Gracell Biotech announced that it had...
Via
Talk Markets
Medicare Negotiation Hammers Biotech Stocks Regeneron, Halozyme
March 16, 2023
It's still unclear whether CMS will include those drugs in its negotiation list.
Via
Investor's Business Daily
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
March 15, 2023
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.
Via
InvestorPlace
Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity
March 14, 2023
Via
Benzinga
Where Regeneron Pharmaceuticals Stands With Analysts
March 09, 2023
Via
Benzinga
2 Biotech Stocks You Can Buy and Hold for the Next Decade
March 09, 2023
Regeneron and Sarepta Therapeutics have been on fire so far this year.
Via
The Motley Fool
How Is The Market Feeling About Regeneron Pharmaceuticals?
March 07, 2023
Via
Benzinga
Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading
March 06, 2023
Over the past week, the market had a nice uptick making it harder for defensive sectors like healthcare to get traction up only 0.51% and down almost 5% YTD.
Via
Talk Markets
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 5 Years
March 06, 2023
Via
Benzinga
Sanofi Could Be on a Roll With a Strong Performance and Its Latest FDA Approval
March 06, 2023
The French drug company got the nod for a hemophilia treatment.
Via
The Motley Fool
FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For Stiffness, Pain In Muscles
March 01, 2023
Via
Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today
February 22, 2023
Via
Benzinga
2 Biotech Stocks That Could Help Set You Up for Life
February 11, 2023
The two companies have seen similar share growth over the past year.
Via
The Motley Fool
The Next Generation Of Cancer Vaccines Are Coming; What That Means For Moderna And Other Biotech Stocks
February 24, 2023
Startling cancer vaccine results from Moderna may point to the next big thing in biotech.
Via
Investor's Business Daily
Apellis Surges To Four-Month High — Sending Rival Iveric Tumbling — On A First-Ever Approval
February 21, 2023
Apellis is soon to launch its newest drug, Syfovre, for geographic atrophy patients.
Via
Investor's Business Daily
2 Top Healthcare Stocks Defying the Bear Market
February 14, 2023
These companies have impeccable long-term investment theses.
Via
The Motley Fool
Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers
February 13, 2023
Large cap biopharma stocks are off their highs despite reasonable valuations plus dividends.
Via
Talk Markets
ARK Invest: The 7 Words That Explain Why Wall Street Can’t Stand Cathie Wood
February 13, 2023
Why does Wall Street hate Cathie Wood and her ARKK ETF? Seven words show how her focus on innovation divides investors.
Via
InvestorPlace
New 52-Week Highs In 2023
February 13, 2023
20% of stocks in the large-cap Russell 1,000 have made 52-week highs at some point so far in 2023.
Via
Talk Markets
Ocular Therapeutix Shares Jump On Favorable Data From Intravitreal Implant Study In Wet AMD
February 13, 2023
Via
Benzinga
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.